bilateral
TopicsAbout← Feed
BySRSam Reyes·CMCal Morrow·EQEliza Quinn·DPDana Park
BREAKINGMay 15, 2026

The Supreme Court keeps abortion pill mifepristone available by telehealth

The U.S. Supreme Court issued an unsigned order on May 14, 2026, allowing the abortion pill mifepristone to remain available via telehealth prescriptions and mail delivery nationwide, staying a Fifth Circuit appeals court ruling that had reinstated an in-person dispensing requirement. The stay will remain in effect while the underlying appeal proceeds through the lower courts and any subsequent petition to the Supreme Court. Justices Clarence Thomas and Samuel Alito dissented separately.

XLinkedInFacebookThreadsWhatsAppReddit
⚡The conservative argument represents the dominant position. A significant conservative faction disagrees — see The Divide below.

The Supreme Court blocked a ban on mail-order abortion pills, preserving telehealth access across state lines. But what happens when a state that wants to ban abortion can't stop pills from arriving across its borders?

Not familiar with this story? Get context →
Comstock Act as national abortion ban
Liberal
Justice Thomas's dissent doesn't invoke a fringe theory — it invokes the Comstock Act of 1873 to argue that mailing mifepristone is a federal crime, full stop, in every state, regardless of what any legislature has voted. This isn't a think-tank position being floated at a conference. It is the stated view of a sitting Supreme Court justice, and it would make medication abortion illegal in California and Illinois just as surely as in Louisiana.
Conservative
Thomas is one justice writing in dissent — that's the system working, not failing. The Comstock Act argument has been around for years and has not commanded a majority on any court. Treating a solo dissent as a 'roadmap' requires ignoring that seven justices just went the other direction.
Liberal
Seven justices stayed a single ruling — they haven't weighed in on Comstock at all. The fact that Thomas is alone today doesn't mean he'll be alone after the next appointment, and his reasoning is already circulating in Fifth Circuit briefs.
Conservative
If we're going to reason from judicial dissents to future majorities, the same logic cuts both ways — and right now the scoreboard reads seven to two in the direction you're worried about.
Louisiana's veto power over national access
Liberal
The Fifth Circuit's May 1 ruling didn't give Louisiana sovereignty over Louisiana — it gave Louisiana effective veto power over healthcare access in California, Illinois, and New York by stripping a federal regulatory accommodation the FDA granted based on years of safety data. That is not federalism. That is one state using federal courts to export its abortion ban across state lines.
Conservative
Louisiana isn't setting policy for California — it's arguing that a federal agency exceeded its statutory authority under federal law. If the FDA's 2023 REMS modification was procedurally unlawful, striking it down restores the prior federal baseline, which every state was living under before 2023 without catastrophe.
Liberal
The 'prior federal baseline' you're describing meant millions of people — disproportionately lower-income — faced travel costs, lost wages, and days away from work to access a drug with a 26-year safety record. Restoring that baseline isn't neutral; it's a concrete harm with a known address.
Conservative
The remedy for a procedurally defective rule is for the FDA to redo the rulemaking correctly — not to insulate the current rule from review because the policy outcome is preferred.
FDA's evidence basis for removing in-person requirement
Liberal
The in-person dispensing requirement the FDA removed in 2023 wasn't eliminated carelessly — it was eliminated because accumulated data, including the COVID-era mail delivery experience, showed it wasn't medically necessary. When the other side calls this regulatory fiat, they're not presenting alternative safety data. They're presenting a policy preference dressed as a medical concern.
Conservative
You're asking us to treat 'COVID emergency experience' as a rigorous clinical trial that justifies permanently changing a 23-year-old safety protocol. The APA's arbitrary-and-capricious standard doesn't ask whether the outcome is safe — it asks whether the agency gave a reasoned explanation for abandoning a long-standing requirement. Those are different questions.
Liberal
ACOG, peer-reviewed literature, and the FDA's own pharmacovigilance data all support the modification — the APA requires a reasoned explanation, and the agency gave one. Disagreeing with the conclusion isn't the same as identifying an absence of reasoning.
Conservative
Whether the explanation was sufficient under APA standards is exactly what the Fifth Circuit has not yet decided on the merits — confident assertions that the FDA got it right don't substitute for that adjudication.
Democratic legitimacy of Dobbs settlement
Liberal
The argument that Dobbs returned abortion to democratic deliberation is serious — but Louisiana isn't just deliberating within its borders. It's asking federal courts to strip a federal regulatory accommodation from patients in states where voters have democratically protected abortion access. That's not one state governing itself; that's one state's court victory governing everyone.
Conservative
The FDA is not a democratic institution. When it rewrote mifepristone's distribution rules in 2023 without congressional action, it short-circuited exactly the democratic deliberation you're defending. If the democratic settlement matters, it applies to the administrative state too — agencies don't get to resolve contested political questions by issuing regulatory modifications.
Liberal
Congress delegated drug safety authority to the FDA precisely so these decisions track evidence, not election cycles. Calling that delegation anti-democratic inverts the logic of the statute Congress actually passed.
Conservative
Delegation has limits — that's the whole premise of the APA — and whether the 2023 REMS change stayed within those limits is a legal question, not a policy one the FDA gets to answer for itself.
The stay as temporary reprieve, not resolution
Liberal
This stay bought time, but time is not a policy. Abortion access in America now depends entirely on court composition and litigation timelines — a profoundly fragile foundation for a healthcare decision affecting millions of people annually. Congress has the authority to codify medication abortion access and clarify that Comstock doesn't apply to lawfully prescribed medications. That it hasn't is a political failure with real human costs.
Conservative
You're right that the stay resolves nothing on the merits — but that cuts against the triumphalist framing on your side as much as it does against ours. Seven justices maintaining the status quo during litigation is a cautious procedural instinct, not an ideological commitment. When the Fifth Circuit rules on substance, the court that unanimously dodged standing last time may face a case it can't sidestep.
Liberal
Exactly — which is why the legislative failure matters so much. Every round of litigation is another round of uncertainty for patients who can't wait out a five-year appeals timeline. The courts didn't create this instability; Congress's inaction did.
Conservative
If Congress is the right venue — and on a question this contested, it might be — then the FDA's regulatory shortcuts are making that harder, not easier, by letting both sides avoid the political accountability that a floor vote would require.
Conservative's hardest question
The safety data on telehealth mifepristone prescribing is genuinely strong — major medical organizations and peer-reviewed studies support it, which makes the 'inadequate oversight' argument the weakest plank in the conservative case. If the Fifth Circuit focuses on the APA merits, it will have to grapple with the FDA's substantial safety record, which could undercut the arbitrary-and-capricious claim at its core.
Liberal's hardest question
The strongest challenge to this argument is procedural: the seven-justice majority that stayed the ruling included conservatives, which could signal only that they wanted the case fully developed before acting — not that they will ultimately protect telehealth access on the merits. A court that rules carefully before restricting a right is still capable of eventually restricting it.
The Divide
*Even as the Supreme Court preserved telehealth mifepristone access, the conservative justices revealed a fundamental split over how far to go in enforcing abortion restrictions.*
HARD-LINE / COMSTOCK WING
The Court should have allowed the Fifth Circuit ruling to stand, invoking the Comstock Act to frame telehealth mifepristone as a scheme to circumvent Dobbs.
“What is at stake is the perpetration of a scheme to undermine our decision in Dobbs.” — Justice Samuel Alito
INSTITUTIONALIST MAJORITY
Seven conservatives joined the unsigned stay order, choosing procedural caution and the status quo over an immediate sweep to reinstate in-person-only requirements.
The Verdict
Both sides agree
Both sides accept that the FDA's 2023 REMS modification eliminated a requirement that had been in place for over two decades, making this a substantial change to established regulatory practice rather than a minor clarification.
The real conflict
FACTUAL: Whether the FDA's 2023 REMS modification was based on new evidence of safety (liberal position: 26 years of accumulated data, including COVID-era mail delivery) or was a policy choice that failed to justify stripping a longstanding protocol (conservative position: agency assertion without rigorous reasoned explanation of why prior requirements were no longer justified).
What nobody has answered
If the Fifth Circuit finds the FDA did provide a rigorous, evidence-based explanation for eliminating the in-person requirement, will that satisfy the APA standard — or does the fact that the requirement had been in place for 23 years create a presumption that changing it requires something beyond the normal administrative record?
Sources

More debates